KPTI - Antengene's selinexor approved in South Korea for multiple myeloma and diffuse large b-cell lymphoma

Karyopharm Therapeutics' (NASDAQ:KPTI) partner Antengene announces that through a priority review process, the South Korean Ministry of Food and Drug Safety has approved its New Drug Application (NDA) for the Orphan Drug-designated oral inhibitor of XPO1, selinexor (XPOVIO), in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (rrMM) who have received at least four prior therapies; and as a monotherapy for the treatment  of adult patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) who have received at least two prior lines of treatment. In October 2020, selinexor was granted an Orphan Drug Designationin South Korea. "I am confident that this oral selective inhibitor of nuclear export protein, with its practice-changing therapeutic utility, will improve the quality of life of patients with rrMM and rrDLBCL in South Korea, and bring renewed hope to this patient population," commented Minyoung Kim, General Manager of Antengene.

For further details see:

Antengene's selinexor approved in South Korea for multiple myeloma and diffuse large b-cell lymphoma